Elaine Mardis, co-director of the Genome Institute at Washington University in St. Louis, discussed genomic testing for cancer in both clinical research and diagnosis.
The company plans to bring both tissue-based and blood-based targeted sequencing tests through FDA clearance.
The companies are taking the CE-IVD route as opposed to the LDT model in the US due to Europe's distributed prenatal testing market and lower regulatory hurdles.
At the Molecular Medicine Tri-Conference, Guardant Health presented details from a 510-patient clinical validation study.
The lab plans to launch the LDT in the next three to six months with an eye toward US Food and Drug Administration clearance.
In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.
With a new collection, PLOS highlights negative results it has published.
A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.
The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.